Gates Foundation Awards Opko $1M for TB MDx Development | GenomeWeb

NEW YORK (GenomeWeb News) – Opko Health has received a $1 million grant from the Bill and Melinda Gates Foundation for the development of a tuberculosis test, the company announced today.

The grant will support development of a test for distinguishing latent TB from active TB using Opko's molecular diagnostics technology. The Miami-based firm also leverages the technology to create blood-based tests for identifying biomarkers for diseases including neurodegenerative disorders and malignancies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This week in Nature: Researchers describe the adaptation of organisms to environmental changes, while another study provides new insights into pig domestication.

The blog Sartorial Science seeks to challenge the stereotype of scientists as frumpy, messy, clueless dressers.

While one researcher says cloning the mammoth may be decades away, if successful, it may lead to a theme park of species that would no longer be extinct.

DNA Sequencing is being used by researchers in California to survey fish and marine life as part of a conservation effort.

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Oct
29
Sponsored by
Lucigen

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing.